RxDoctor Payments DataLook up a doctor →

Emily Moore

Acute Care · Decatur, ALNPI 1871001412

Payments from drug & device makers

$10,489in general payments, 2019–2025

Across 579 payments — averaging $18.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • SK Life Science, Inc.$668
  • UCB, Inc.$608
  • Neurocrine Biosciences, Inc.$599
  • AstraZeneca$520
  • MDD US Operations, LLC$445
  • plus $6K from 41 others

What the payments were for

  • Speaking & faculty fees$801%
  • Food & beverage$10,38399%
  • Education$270%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,489 in reported general payments places this provider in the 95th percentile of 711 acute care providers in Alabama.

See all acute care providers in Alabama

Medicare billing

Part B allowed, 2024
$73,338
Medicare patients
301
Services billed
800

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate92$146,179
UbrelvyUbrogepant53$64,749
Oxtellar XrOxcarbazepine21$38,159
Lamictal XrLamotrigine21$37,158
AptiomEslicarbazepine Acetate21$32,553
BriviactBrivaracetam15$20,529
Topiramate ErTopiramate18$17,323
Lamotrigine ErLamotrigine42$15,650
FycompaPerampanel11$13,439
Emgality PenGalcanezumab-Gnlm18$12,689
Aimovig AutoinjectorErenumab-Aooe15$12,023
Lacosamide47$8,180
Memantine Hcl205$6,678
Levetiracetam216$6,151
Divalproex Sodium ErDivalproex Sodium135$6,077

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerNurtec Odt, Dilantin$227$151,041114 claims
AbbVieUbrelvy$1,771$64,74953 claims
Supernus Pharmaceuticals, Inc.Oxtellar Xr$219$38,15921 claims
Sunovion Pharmaceuticals Inc.Aptiom$190$32,55321 claims
UCB, Inc.Briviact$608$20,52915 claims
Eisai Inc.Fycompa$376$13,43911 claims
Upsher-smith Laboratories LLCTopiramate$29$1,558131 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$120$1,13519 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 711 acute care providers in Alabama.

Other acute care in Decatur

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →